Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Nutrients ; 16(6)2024 Mar 12.
Artículo en Inglés | MEDLINE | ID: mdl-38542718

RESUMEN

Longitudinal studies assessing the association of vitamin D deficiency, defined by serum 25-hydroxyvitamin D levels < 30 nmol/L, and vitamin D supplement (VDS) use with low back pain (LBP) are sparse. This investigation assessed the cross-sectional and longitudinal association of vitamin D status and VDS use with LBP among 135,934 participants from the UK Biobank cohort. Approximately 21.6% of the participants had vitamin D deficiency, while only 4% regularly took VDS. In the month before study enrollment, 3.8% of the population reported experiencing LBP. An additional 3.3% of the population were diagnosed with LBP by their general practitioners for the first time during a median follow-up of 8.5 years. Vitamin D deficiency and VDS use were cross-sectionally associated with LBP in age- and sex-adjusted models, but these associations were not evident in comprehensively adjusted models. In longitudinal analyses, both vitamin D deficiency and VDS use were not associated with LBP in any model after correction for multiple testing. In conclusion, not unexpectedly due to the fact that LBP is multifactorial, our findings provide no evidence for the role of the vitamin D status in the etiology of LBP.


Asunto(s)
Dolor de la Región Lumbar , Deficiencia de Vitamina D , Vitamina D/análogos & derivados , Humanos , Dolor de la Región Lumbar/epidemiología , Dolor de la Región Lumbar/etiología , Estudios Transversales , Bancos de Muestras Biológicas , Biobanco del Reino Unido , Vitaminas , Suplementos Dietéticos/efectos adversos , Calcifediol
2.
Am J Clin Nutr ; 119(4): 1052-1064, 2024 04.
Artículo en Inglés | MEDLINE | ID: mdl-38296029

RESUMEN

BACKGROUND: Prior studies on vitamin D and dementia outcomes yielded mixed results and had several important limitations. OBJECTIVES: We aimed to assess the associations of both serum vitamin D status and supplementation with all-cause dementia, Alzheimer's disease (AD), and vascular dementia (VD) incidence. METHODS: With a prospective cohort study design, we comprehensively assessed the associations of vitamin D and multivitamin supplementation, as well as vitamin D deficiency {25-hydroxyvitamin D [25(OH)D] <30 nmol/L}, and insufficiency [25(OH)D 30 to <50 nmol/L], with the 14-year incidence of all-cause dementia, AD, and VD in 269,229 participants, aged 55 to 69, from the UK Biobank. RESULTS: Although 5.0% reported regular vitamin D use and 19.8% reported multivitamin use, the majority of participants exhibited either vitamin D deficiency (18.3%) or insufficiency (34.0%). However, vitamin D deficiency was less prevalent among users of vitamin D (6.9%) or multivitamin preparations (9.5%) than among nonusers (21.5%). Adjusted Cox regression models demonstrated 19% to 25% increased risk of all 3 dementia outcomes for those with vitamin D deficiency [hazard ratio (HR) 95% confidence interval (CI)]: 1.25 (1.16, 1.34) for all-cause dementia; 1.19 (1.07-1.31) for AD; 1.24 (1.08-1.43) for VD] and 10% to 15% increased risk of those with vitamin D insufficiency [HR (95% CI): 1.11 (1.05, 1.18) for all-cause dementia; 1.10 (1.02-1.19) for AD; 1.15 (1.03-1.29) for VD]. Regular users of vitamin D and multivitamins had 17% and 14% lower risk of AD [HR (95% CI): 0.83 (0.71, 0.98)] and VD [HR (95% CI): 0.86 (0.75, 0.98)] incidence, respectively. CONCLUSIONS: Although our findings indicate the potential benefits of vitamin D supplementation for dementia prevention, randomized controlled trials are essential for definitive evidence.


Asunto(s)
Enfermedad de Alzheimer , Demencia Vascular , Demencia , Deficiencia de Vitamina D , Humanos , Enfermedad de Alzheimer/epidemiología , Enfermedad de Alzheimer/prevención & control , Demencia Vascular/epidemiología , Demencia Vascular/etiología , Demencia Vascular/prevención & control , Demencia/epidemiología , Demencia/prevención & control , Estudios Prospectivos , Biobanco del Reino Unido , Bancos de Muestras Biológicas , Factores de Riesgo , Vitamina D , Deficiencia de Vitamina D/epidemiología , Deficiencia de Vitamina D/prevención & control , Vitaminas/uso terapéutico , Suplementos Dietéticos
3.
Eur J Cancer ; 191: 113241, 2023 09.
Artículo en Inglés | MEDLINE | ID: mdl-37549530

RESUMEN

BACKGROUND: Although the associations of serum 25-hydroxyvitamin D (25(OH)D) levels and vitamin D supplementation with total cancer mortality are well-known, evidence regarding the association of 25(OH)D and cancer site-specific mortality is predominantly limited to common cancer types, and most studies on vitamin D supplementation use have limitations on sample size and the adjustment of important confounding factors. METHODS: We used cause-specific Cox regression models adjusted for 48 covariates to assess the associations of vitamin D deficiency, insufficiency, and vitamin D supplementation use with mortality from any cancer and 18 specific cancers in 411,436 United Kingdom Biobank participants, aged 40-69 years. RESULTS: The majority of the study population had either vitamin D deficiency (21.1%) or insufficiency (34.4%). Furthermore, 4.1% and 20.3% of the participants regularly took vitamin D or multivitamin supplements, respectively. During a median follow-up of 12.7 years, vitamin D deficiency was associated with significantly increased mortality from total cancer and four specific cancers: stomach (hazard ratio, 95% confidence interval: 1.42, 1.05-1.92), colorectal (1.27, 1.07-1.50), lung (1.24, 1.10-1.40), and prostate (1.36, 1.06-1.75). Vitamin D insufficiency was associated with increased colorectal (1.14, 1.00-1.30) and lung cancer mortality (1.19, 1.08-1.32). Compared to non-users, vitamin D use was associated with lower lung cancer (0.75, 0.60-0.95) and total cancer mortality. Multivitamin use was associated with lower mortality from melanoma (0.64, 0.43-0.97). CONCLUSION: Vitamin D deficiency and insufficiency were associated with increased mortality from multiple common cancers. The potential to reduce cancer mortality by vitamin D supplementation in populations with low 25(OH)D levels should be further explored.


Asunto(s)
Neoplasias Colorrectales , Neoplasias Pulmonares , Deficiencia de Vitamina D , Masculino , Humanos , Bancos de Muestras Biológicas , Vitamina D , Vitaminas , Deficiencia de Vitamina D/epidemiología , Suplementos Dietéticos
4.
Ageing Res Rev ; 87: 101923, 2023 06.
Artículo en Inglés | MEDLINE | ID: mdl-37004841

RESUMEN

To evaluate the effect of vitamin D3 supplementation on cancer mortality in the general population and on prognosis in cancer patients, a systematic review and meta-analysis of randomised, placebo-controlled trials (RCTs) and individual patient data (IPD) was conducted. Overall, 14 RCTs with a total of 104,727 participants (2015 cancer deaths) were identified and 7 RCTs, including 90 % of all study participants (n = 94,068), could be included in the IPD meta-analyses. The main meta-analysis of the 14 RCTs yielded a statistically non-significant reduction in cancer mortality by 6 % (risk ratio (RR) [95%-confidence interval (95%CI)]: 0.94 [0.86-1.02]). Subgroup analyses revealed a 12 % lower cancer mortality in the vitamin D3 group compared with the placebo group in 10 trials with a daily dosing regimen (RR [95%CI]: 0.88 [0.78-0.98]), whereas no mortality reduction was seen in 4 trials using a bolus regimen (RR [95%CI]: 1.07 [0.91-1.24]; p-value for interaction: 0.042). The IPD meta-analysis (RR [95%CI]: 0.93 [0.84; 1.02]) confirmed the finding of all trials. The IPD were used to test effect modification by age, sex, body mass index, ethnicity, baseline serum 25-hydroxyvitamin D concentration, adherence and cancer-related factors but no statistically significant findings were obtained in meta-analyses of all trials. When restricted to trials with daily dosing in a post-hoc analysis, adults aged ≥ 70 years (RR [95%CI]: 0.83 [0.77; 0.98]) and subjects with vitamin D3 therapy initiation before cancer diagnosis (RR [95%CI]: 0.87 [0.69; 0.99]) appeared to benefit most from daily vitamin D3 supplementation. Measurements of baseline 25-hydroxyvitamin D levels and inclusion of other than non-Hispanic White adults were too sparse in the trials to draw conclusions. Results for all-cause and cancer-specific survival of participants with cancer were comparable to those obtained in the general population for cancer mortality. In conclusion, vitamin D3 did not reduce cancer mortality in the main meta-analysis of all RCTs because the observed risk reduction by 6 % was not statistically significant. However, a subgroup analysis revealed that vitamin D3 administered daily, in contrast to bolus supplementation, reduced cancer mortality by 12 %.


Asunto(s)
Colecalciferol , Neoplasias , Humanos , Colecalciferol/uso terapéutico , Suplementos Dietéticos , Neoplasias/tratamiento farmacológico , Pronóstico , Vitamina D
5.
Sci Rep ; 7(1): 1728, 2017 05 11.
Artículo en Inglés | MEDLINE | ID: mdl-28496142

RESUMEN

This study aimed to investigate the role of src-homology protein tyrosine phosphatase-1 (SHP-1)-signal transducer and activator of transcription 3 (STAT3) pathway in liver fibrogenesis and the anti-fibrotic effect of SHP-1 agonist. The antifibrotic activity of SC-43, a sorafenib derivative with an enhanced SHP-1 activity, was evaluated in two fibrosis mouse models by carbon tetrachloride induction and bile duct ligation. Rat, human, and primary mouse hepatic stellate cells (HSCs) were used for mechanistic investigations. The results showed that SHP-1 protein primarily localized in fibrotic areas of human and mouse livers. SC-43 treatment reduced the activated HSCs and thus effectively prevented and regressed liver fibrosis in both fibrosis mouse models and improved mouse survival. In vitro studies revealed that SC-43 promoted HSC apoptosis, increased the SHP-1 activity and inhibited phospho-STAT3. The enhanced SHP-1 activity in HSCs significantly inhibited HSC proliferation, whereas SHP-1 inhibition rescued SC-43-induced HSC apoptosis. Furthermore, SC-43 interacted with the N-SH2 domain of SHP-1 to enhance the activity of SHP-1 as its antifibrotic mechanism. In conclusion, the SHP-1-STAT3 pathway is crucial in fibrogenesis. SC-43 significantly ameliorates liver fibrosis through SHP-1 upregulation. A SHP-1-targeted antifibrotic therapy may represent a druggable strategy for antifibrotic drug discovery.


Asunto(s)
Cirrosis Hepática/tratamiento farmacológico , Éteres Fenílicos/uso terapéutico , Compuestos de Fenilurea/uso terapéutico , Proteína Tirosina Fosfatasa no Receptora Tipo 6/metabolismo , Animales , Apoptosis/efectos de los fármacos , Conductos Biliares/patología , Tetracloruro de Carbono , Línea Celular , Proliferación Celular/efectos de los fármacos , Modelos Animales de Enfermedad , Células Estrelladas Hepáticas/efectos de los fármacos , Células Estrelladas Hepáticas/metabolismo , Humanos , Ligadura , Cirrosis Hepática/patología , Cirrosis Hepática/prevención & control , Masculino , Ratones Endogámicos C57BL , Mutación/genética , Éteres Fenílicos/química , Éteres Fenílicos/farmacología , Compuestos de Fenilurea/química , Compuestos de Fenilurea/farmacología , Dominios Proteicos , Proteína Tirosina Fosfatasa no Receptora Tipo 6/química , Ratas , Factor de Transcripción STAT3/metabolismo , Sorafenib/química , Sorafenib/farmacología , Sorafenib/uso terapéutico
6.
BMC Health Serv Res ; 16: 261, 2016 07 13.
Artículo en Inglés | MEDLINE | ID: mdl-27412399

RESUMEN

BACKGROUND: To assess the utilization of and satisfaction with ophthalmic healthcare provided by integrated delivery system (IDS) since 2000 and vision-related quality of life (VRQoL) for residents of an offshore island of Taiwan. METHODS: Facilitators interviewed residents (age ≥ 50 years) with the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) for VRQoL and a questionnaire on clinical information, ophthalmic care utilization and satisfaction. RESULTS: A total of 841 participants (response rate 93.4 %, 841/900) completed the questionnaire survey. Mean age was 63.7 (±10. 7) years. The common eye diseases were cataract (44.7 %), dry eye (15.5 %), and glaucoma (8.7 %). Among the participants, 61.0 % sought ophthalmic care under the IDS in the past year and 17.6 % experienced unmet ophthalmic needs in the past 6 months. Satisfaction with ophthalmic care under the IDS was 88.1 %. Determinants of dissatisfaction under the IDS were distance to healthcare facility and VRQoL. Predictors of VRQoL included age, residential area, marital status, occupation, comorbid condition, commercial insurance, household income, cataracts and glaucoma. CONCLUSIONS: The implementation of IDS improves accessibility of ophthalmic care for residents of an offshore island. Geographic proximity to avail healthcare facility and VRQoL affect satisfaction with the IDS.


Asunto(s)
Accesibilidad a los Servicios de Salud/estadística & datos numéricos , Satisfacción del Paciente , Calidad de Vida , Visión Ocular , Anciano , Anciano de 80 o más Años , Prestación Integrada de Atención de Salud/estadística & datos numéricos , Oftalmopatías/diagnóstico , Oftalmopatías/terapia , Femenino , Humanos , Masculino , Persona de Mediana Edad , Programas Nacionales de Salud , Oftalmología , Análisis de Regresión , Encuestas y Cuestionarios , Taiwán
7.
World J Gastroenterol ; 20(30): 10525-30, 2014 Aug 14.
Artículo en Inglés | MEDLINE | ID: mdl-25132771

RESUMEN

AIM: To present our experience with refeeding syndrome in southeastern Taiwan. METHODS: We conducted a retrospective study during a 2-year period at the Mackay Memorial Hospital, Taitung Branch. We enrolled patients with very little or no nutrition intake for more than 10 d, a high risk group of refeeding syndrome, including those suffering from alcohol abuse, cancerous cachexia, chronic malnutrition, and prolonged starvation. RESULTS: A total of 11 patients (7 males, 4 females) with nasogastric feeding were included as having refeeding syndrome. Most of them had the symptoms of diarrhea, lethargy, and leg edema. The initial nutritional supplement was found to be relatively high in calories (1355.1 ± 296.2 kcal/d), high in protein (47.3 ± 10.4 gm/d), low in vitamin B1 (2.0 ± 0.5 mg/d), low in potassium (1260.4 ± 297.7 mg/d), and low in phosphorus (660.1 ± 151.8 mg/d). Furthermore, hypophosphatemia (2.4 ± 0.9 mg/dL) was noted during follow-up. Based on the suggestions of a dietician and a gastroenterologist, the clinical disorders of diarrhea, malaise and leg edema were significantly improved. The level of phosphate was also increased (3.3 ± 0.6 mg/dL). CONCLUSION: Refeeding syndrome is an overlooked and risky disorder that has some potentially fatal complications. Nasogastric feeding in nursing homes is an important risk factor for patients and deserves greater attention based on the initial results of this study.


Asunto(s)
Nutrición Enteral/efectos adversos , Desnutrición/terapia , Nutrición Parenteral Total/efectos adversos , Síndrome de Realimentación/etiología , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Intubación Gastrointestinal , Masculino , Desnutrición/diagnóstico , Desnutrición/fisiopatología , Persona de Mediana Edad , Estado Nutricional , Síndrome de Realimentación/diagnóstico , Síndrome de Realimentación/fisiopatología , Síndrome de Realimentación/terapia , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Taiwán , Resultado del Tratamiento
8.
Head Neck ; 33(2): 257-66, 2011 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-20848451

RESUMEN

BACKGROUND: This study was undertaken to identify the genes in response to areca nut extract, a potential carcinogen of oral cancer. METHODS: Two oral cancer sublines chronically treated with areca nut extract were established. Methods such as microarray and immunohistochemistry were used to screen and validate the genes' altered expressions in areca nut extract-sublines or in cancer tissues. RESULTS: A total of 35 genes were differentially expressed in both sublines. Several functional pathways were significantly altered. Six genes were confirmed over 2-fold of changes, including Ches1. Functional analyses showed that overexpression of Ches1 suppressed cell growth and arrested cells in the G2/M phase. Consistently, this gene has reduced expression in 52% of oral cancer tissues, which was significantly correlated with the areca nut chewing habit of patients (p = .04). CONCLUSION: We identified 35 candidates and validated 6 genes that may be associated with areca nut-induced oral cancer. Loss of Ches1 may be attributed to areca nut extract-induced oral carcinogenesis.


Asunto(s)
Areca , Biomarcadores de Tumor/metabolismo , Proteínas de Ciclo Celular/metabolismo , Neoplasias de la Boca/genética , Fitoterapia/efectos adversos , Extractos Vegetales/toxicidad , Proteínas Represoras/metabolismo , Biomarcadores de Tumor/genética , Biomarcadores de Tumor/inmunología , Proteínas de Ciclo Celular/genética , Proteínas de Ciclo Celular/inmunología , División Celular/genética , Transformación Celular Neoplásica/genética , Transformación Celular Neoplásica/metabolismo , Regulación hacia Abajo/efectos de los fármacos , Femenino , Factores de Transcripción Forkhead , Genes/efectos de los fármacos , Humanos , Inmunohistoquímica , Técnicas In Vitro , Masculino , Masticación/efectos de los fármacos , Persona de Mediana Edad , Mucosa Bucal/efectos de los fármacos , Neoplasias de la Boca/inducido químicamente , Neoplasias de la Boca/metabolismo , Polimorfismo de Nucleótido Simple/genética , Análisis por Matrices de Proteínas , Proteínas Represoras/genética , Proteínas Represoras/inmunología , Células Tumorales Cultivadas , Regulación hacia Arriba
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA